benign prostatic hyperplasia
Conditions
Interventions
Experimental group:PAE with bleomycin-eluting 30 - 60 um microspheres
Control group:PAE combined with 40-120um Embosphere and PVA-100
Sponsors
Chinese PLA General Hospital
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: Patients older than 50 years of age with a diagnosis of severe lower urinary tract symptoms (International Prostate Symptom Score [IPSS]>8, quality of life [QoL] score>3, peak urinary flow rate [Qmax]6 months) and prostate volume (PV) greater than 50 mL. Prostate biopsy was performed in men with prostatespecific antigen (PSA) levels greater than 4.0 ng/mL to exclude malignancy; Not suitable or unwilling to accept surgical treatment due to comorbidities.
Exclusion criteria
Exclusion criteria: Patients who have underwent PAE or prostatectomypriviously; active prostatitis or urinary tract infection; neurogenic bladder or detrusor failure; prostate malignancy; large (>5 cm) bladder diverticula; chronic renal failure; urethral stricture; coagulopathies; allergic to iodine contrast medium; with mental disorders; can not complete postoperative follow-up; and the presence of a cardiac pacemaker, a nerve stimulator, or other metal implants.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| International Prostate Symptom (IPSS) Score; | — |
Secondary
| Measure | Time frame |
|---|---|
| prostate volume;post-void urine residual volume;quality of life(QoL);prostate-specific antigen (PSA);prostate-specific antigen (PSA); | — |
Countries
China
Contacts
Public ContactWang Mao-Qiang
Chinese PLA General Hospital
Outcome results
None listed